CJC-1295 + Ipamorelin Australia research centres on a two-peptide GH-axis blend combining a GHRH receptor agonist with a selective ghrelin receptor (GHS-R) agonist in a single vial. Rather than two compounds working through the same mechanism, this blend pairs complementary receptors within the same growth hormone secretion pathway — a combination strategy distinct from the multi-mechanism blends like GLOW and KLOW covered elsewhere in our research range. This guide covers each compound's individual mechanism, why they're studied together, and the practical handling steps for research.

Key Research Points at a Glance

• Combines CJC-1295 No DAC (CAS 863288-34-0), a GHRH receptor agonist, with Ipamorelin (CAS 170851-70-4), a selective ghrelin receptor (GHS-R) agonist
• Both compounds act within the GH-axis but through genuinely distinct receptors — a complementary rather than duplicate combination
• Studied together for potential synergistic stimulation of growth hormone release via two separate signalling inputs
• Ipamorelin's receptor selectivity is studied for minimal cortisol and prolactin co-release compared to older, less selective secretagogues
• CJC-1295 No DAC lacks the Drug Affinity Complex (DAC) modification, distinguishing it from extended-half-life CJC-1295 research
• Frequently searched as "CJC-1295 Ipamorelin blend Australia" by researchers comparing combination GH-axis research vials

Why Combine CJC-1295 and Ipamorelin?

Growth hormone release from the pituitary is regulated by at least two separate receptor systems: the GHRH receptor and the ghrelin receptor (GHS-R). CJC-1295 No DAC targets the former, Ipamorelin the latter. Because these are separate, complementary signalling inputs into the same overall GH-axis pathway rather than two compounds competing for the same receptor, researchers studying combined or synergistic GH-axis stimulation often examine both together rather than relying on either compound alone.

CJC-1295 No DAC: GHRH Receptor Mechanism

CJC-1295 No DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH), studied for stimulating growth hormone release via direct GHRH receptor activation on pituitary somatotroph cells. The "No DAC" designation means this version lacks the Drug Affinity Complex modification used in extended-half-life CJC-1295 research, giving it a shorter research half-life more comparable to native GHRH.

Ipamorelin: Selective Ghrelin Receptor Mechanism

Ipamorelin is a pentapeptide studied as a highly selective ghrelin receptor (GHS-R) agonist. Its research interest centres on its selectivity — compared to older, less selective growth hormone secretagogues, Ipamorelin is studied for stimulating growth hormone release with comparatively minimal effect on cortisol and prolactin levels, a research characteristic that distinguishes it within the broader secretagogue category.

Why This Combination Is a Genuinely Complementary Pairing

Unlike multi-mechanism blends such as GLOW or KLOW — which combine compounds from entirely different research categories (cosmetic, regenerative) — CJC-1295 and Ipamorelin both sit squarely within GH-axis research, but at two distinct points in the same pathway. This makes the combination mechanistically coherent: researchers aren't combining unrelated systems, but rather studying two separate inputs converging on the same downstream growth hormone release outcome. See our growth hormone peptide guide for the broader GH-axis research category.

Research Context: Combination vs Single-Compound Study Designs

Researchers may choose to study CJC-1295 and Ipamorelin individually to isolate each receptor's specific contribution, or study them combined to examine potential synergistic or additive effects on growth hormone release. Both approaches appear in the research literature, and the appropriate choice depends on the specific research question being investigated — mechanism isolation versus combined pathway behaviour.

Relationship to Other GH-Axis Research Peptides

This blend sits alongside other GH-axis compounds in PhaseOne's research range, including HGH 191AA (a direct growth hormone analogue, downstream of GHRH/ghrelin receptor signalling) and IGF-1 LR3 (further downstream, mediating many of growth hormone's research effects). Researchers studying the full GH-axis pathway may examine compounds at each stage — GHRH/ghrelin receptor stimulation, direct GH analogues, and downstream IGF-1 signalling — depending on which part of the pathway their research question targets.

Animal-Model and Cellular Research Context

Both CJC-1295 and Ipamorelin have research bases spanning cellular and animal-model studies of GHRH and ghrelin receptor pharmacology respectively. As with all GH-axis research compounds, findings should be evaluated within the specific research model studied rather than generalised across contexts.

Common Misconceptions About This Blend

A frequent misconception is assuming CJC-1295 and Ipamorelin work through the same mechanism because both are studied for growth hormone release — they act on entirely separate receptors (GHRH receptor and ghrelin receptor respectively), and this distinction is precisely why the combination is research-relevant rather than redundant. A second misconception is confusing CJC-1295 No DAC with standard CJC-1295; the DAC modification specifically extends half-life and is absent from the No DAC version used in this blend.

Reconstitution, Storage and Handling

This blend ships as a lyophilised (freeze-dried) powder. Reconstitution requires bacteriostatic water — see our reconstitution guide for the process and our peptide dosage calculator for concentration calculations.

Once reconstituted, refrigerate immediately and protect from light. See our storage guide for the full set of stability variables.

Verifying CJC-1295 + Ipamorelin Purity

Every PhaseOne CJC-1295 + Ipamorelin batch is independently tested via High Performance Liquid Chromatography (HPLC) and ships with a batch-specific Certificate of Analysis verifying both peptide components. See our HPLC testing guide and research standards guide for the full process.

Related Research Guides

For each individual compound, see our CJC-1295 and Ipamorelin guides. For the broader GH-axis research category, see our growth hormone peptide guide . For handling, see our reconstitution guide and storage guide .

Sourcing CJC-1295 + Ipamorelin in Australia

Researchers searching for a CJC-1295 Ipamorelin blend Australia supplier should prioritise vendors who provide independent, batch-specific HPLC verification confirming both components' identity and purity. PhaseOne supplies this blend alongside the broader GH-axis research category — including HGH 191AA and IGF-1 LR3 — with the same third-party testing standard applied across every product, shipped Australia-wide.

Frequently Asked Questions

Why combine CJC-1295 and Ipamorelin?

Each targets a different receptor within the same growth hormone secretion pathway — CJC-1295 the GHRH receptor, Ipamorelin the ghrelin receptor (GHS-R) — making the combination mechanistically complementary rather than redundant.

Do CJC-1295 and Ipamorelin work through the same mechanism?

No — CJC-1295 No DAC is a GHRH receptor agonist, while Ipamorelin is a selective ghrelin receptor agonist. They act on separate receptors that both feed into growth hormone release.

What does 'No DAC' mean in CJC-1295 No DAC?

It indicates the absence of the Drug Affinity Complex modification used in standard CJC-1295, which extends half-life. CJC-1295 No DAC has a shorter research half-life, closer to native GHRH.

Why is Ipamorelin studied for its receptor selectivity?

Ipamorelin is a highly selective ghrelin receptor agonist studied for stimulating growth hormone release with comparatively minimal effect on cortisol and prolactin, compared to older, less selective secretagogues.

Is this blend related to HGH 191AA or IGF-1 LR3?

Yes — all three sit within the broader GH-axis research pathway. CJC-1295/Ipamorelin act upstream at the GHRH/ghrelin receptor level, HGH 191AA is a direct growth hormone analogue, and IGF-1 LR3 acts further downstream.

How should this blend be reconstituted?

Using bacteriostatic water, following the same general process as other lyophilised research peptides, with immediate refrigeration and light protection after reconstitution.

How is purity verified for this blend?

PhaseOne verifies every batch via independent third-party HPLC testing with a batch-specific Certificate of Analysis confirming both peptide components.

Where can I buy a CJC-1295 + Ipamorelin blend in Australia?

PhaseOne supplies this blend for research purposes Australia-wide, with independent batch-specific HPLC testing for every product.

Disclaimer

All products supplied by PhaseOne are intended strictly for laboratory research purposes only. Products are not intended for human consumption, therapeutic use, cosmetic use, veterinary use, or diagnostic applications.